EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beyond Traditional Screening: The Future of Heart Failure Detection With Biomarkers and AI

Xiaofeng Fang, Yinbo Xu, Yiting Zhao, Liuyi Li, Zhengyi Cheng, Zhongqi Zhang, Yuhang Luo, Qiaoling Liu, Chen Gong, Shichun Shen

iNew Medicine · 2026-09 · 2 (3)

DOI: 10.1002/inm3.70051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift iNew Medicine, online erschienen am 24.04.2026. Verfasst von Xiaofeng Fang und 9 weiteren Autor:innen. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Anhui Province.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure (HF) continues to be a leading cause of death and disability globally, with an estimated annual prevalence of over 56 million patients and a projected significant increase in occurrence. Although drug treatments based on existing guidelines can enhance the clinical prognosis for patients with HF, the five‐year survival rate remains below 50%. This underscores the critical need for early detection and effective strategies to prevent and manage the progression of HF. Present screening approaches, encompassing individual biomarkers and imaging techniques, exhibit shortcomings in identifying subclinical or incipient‐stage diseases. This review amalgamates the most recent advancements in HF screening, specifically highlighting novel biomarkers that correspond to various pathways involved in cardiac remodeling, inflammation, neurohormones, and emerging pathophysiological pathways. Several emerging biomarkers, notably sST2 and GDF‐15, demonstrate strong potential for inclusion in future clinical guidelines, enhancing early risk stratification and personalized screening. Artificial intelligence‐driven approaches, integrating electrocardiograms, wearable devices, and analysis of medical images using machine learning and multimodal data, represent a promising strategy for improving early risk identification. Nevertheless, it is imperative for researchers to systematically address enduring challenges. These challenges encompass analytical variability in machine learning data, the absence of multicenter clinical trial data, constraints in hardware deployment, and biases prevalent in resource‐limited settings. Future research endeavors should prioritize the integration of multi‐omics technologies, thereby enhancing the precision of biomarkers. This would enhance biomarker accuracy, facilitate dynamic risk stratification for HF, and guarantee equitable global implementation. Combining evidence‐based methodologies with technological innovation will be fundamental to developing scalable screening tools. Implementing such a stepwise integrated screening framework will allow clinicians to optimize therapeutic timing and improve survival outcomes in HF management.

Förderung

  • Natural Science Foundation of Anhui Province

Zitieren

APA

Fang, X., Xu, Y., Zhao, Y., Li, L., Cheng, Z., Zhang, Z., Luo, Y., Liu, Q., Gong, C., & Shen, S. (2026). Beyond Traditional Screening: The Future of Heart Failure Detection With Biomarkers and AI. iNew Medicine, 2(3). https://doi.org/10.1002/inm3.70051

Vancouver

Fang X, Xu Y, Zhao Y, Li L, Cheng Z, Zhang Z, et al. Beyond Traditional Screening: The Future of Heart Failure Detection With Biomarkers and AI. iNew Medicine. 2026;2(3). doi:10.1002/inm3.70051

BibTeX
@article{Fang2026,
  author = {Fang, Xiaofeng and Xu, Yinbo and Zhao, Yiting and Li, Liuyi and Cheng, Zhengyi and Zhang, Zhongqi and Luo, Yuhang and Liu, Qiaoling and Gong, Chen and Shen, Shichun},
  title = {Beyond Traditional Screening: The Future of Heart Failure Detection With Biomarkers and AI},
  journal = {iNew Medicine},
  year = {2026},
  volume = {2},
  number = {3},
  doi = {10.1002/inm3.70051}
}
Kostenlos starten →